within Pharmacolibrary.Drugs.ATC.N;

model N06BA15
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.22,
    Cl             = 0.4 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 39.2 / 1000000,
    adminCount     = 1,
    Vd             = 0.00265,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Dexmethylphenidate is the d-threo-enantiomer of methylphenidate, a central nervous system stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Serdexmethylphenidate is a prodrug of dexmethylphenidate designed for extended-release formulations. The combination is approved and marketed for the treatment of ADHD.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults based on known pharmacokinetics of dexmethylphenidate and serdexmethylphenidate (CNS stimulant, oral administration). No published non-compartmental or compartmental population PK modeling reports currently available; estimates extrapolated from clinical pharmacology data.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N06BA15;
